Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Twinbeech Capital LP

Twinbeech Capital LP grew its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 79.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 355,900 shares of the company's stock after acquiring an additional 157,321 shares during the quarter. Twinbeech Capital LP owned about 0.42% of Syndax Pharmaceuticals worth $4,705,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SNDX. Tang Capital Management LLC purchased a new stake in shares of Syndax Pharmaceuticals during the 4th quarter worth about $1,322,000. Sphera Funds Management LTD. grew its holdings in shares of Syndax Pharmaceuticals by 33.5% during the 4th quarter. Sphera Funds Management LTD. now owns 1,381,241 shares of the company's stock worth $18,260,000 after purchasing an additional 346,395 shares during the period. Rafferty Asset Management LLC grew its holdings in shares of Syndax Pharmaceuticals by 3.9% during the 4th quarter. Rafferty Asset Management LLC now owns 178,165 shares of the company's stock worth $2,355,000 after purchasing an additional 6,643 shares during the period. Polar Asset Management Partners Inc. purchased a new stake in shares of Syndax Pharmaceuticals during the 4th quarter worth about $1,124,000. Finally, ProShare Advisors LLC grew its holdings in shares of Syndax Pharmaceuticals by 32.2% during the 4th quarter. ProShare Advisors LLC now owns 27,183 shares of the company's stock worth $359,000 after purchasing an additional 6,627 shares during the period.

Syndax Pharmaceuticals Stock Down 8.9%

Shares of Syndax Pharmaceuticals stock traded down $0.96 on Friday, hitting $9.85. 3,902,175 shares of the company's stock traded hands, compared to its average volume of 1,770,764. The stock has a market cap of $847.56 million, a P/E ratio of -2.71 and a beta of 0.82. The firm's 50-day moving average is $11.83 and its 200 day moving average is $13.80. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. The business's revenue was up 1900.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.85) earnings per share. Equities research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SNDX. JPMorgan Chase & Co. boosted their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 20th. Guggenheim restated a "buy" rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Citigroup decreased their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Wall Street Zen upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. Finally, HC Wainwright restated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.91.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).